1. Home
  2. ASA vs HROW Comparison

ASA vs HROW Comparison

Compare ASA & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ASA

ASA Gold and Precious Metals Limited

HOLD

Current Price

$69.78

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Logo Harrow Inc.

HROW

Harrow Inc.

HOLD

Current Price

$30.20

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASA
HROW
Founded
1958
1998
Country
United States
United States
Employees
N/A
373
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.4B
IPO Year
2003
N/A

Fundamental Metrics

Financial Performance
Metric
ASA
HROW
Price
$69.78
$30.20
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$69.86
AVG Volume (30 Days)
48.8K
787.4K
Earning Date
06-01-2026
05-11-2026
Dividend Yield
0.10%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$31.62
Revenue Next Year
N/A
$50.77
P/E Ratio
$1.96
N/A
Revenue Growth
N/A
N/A
52 Week Low
$28.67
$25.21
52 Week High
$83.20
$54.98

Technical Indicators

Market Signals
Indicator
ASA
HROW
Relative Strength Index (RSI) 57.13 26.56
Support Level $65.80 N/A
Resistance Level $72.77 $41.67
Average True Range (ATR) 2.52 1.95
MACD 0.58 -1.31
Stochastic Oscillator 78.07 8.76

Price Performance

Historical Comparison
ASA
HROW

About ASA ASA Gold and Precious Metals Limited

ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Share on Social Networks: